Fully automatic brain CT emergency abnormality detection
Based on computer vision and deep learning technology, VeriScoutTM provides fully automatic real-time detection and triaging of cerebral haemorrhage cases
Trained on nearly 40,000 clinical cases, VeriScoutTM uses artificial intelligence technology to efficiently detect brain haemorrhage in non-contrast head CT images in real time. The software thereby identifies patients with potentially critical abnormalities and triages these cases for priority reporting by radiologists. Heatmap ‘preview’images provide radiologists with immediate insight into the decision reasoning of Veriscout’s underlying AI architecture. Veriscout’s performance for the detection of a variety of cerebral haemorrhage types has been validated by comparison with standard clinical review by expert radiologists, achieving a sensitivity of 93.17% and a specificity of 96.86%. VeriScoutTM seamlessly integrates into existing PACS/RIS workflows with SNAC’s dedicated Torana Medical Imaging Gateway, ensuring no additional clinician burden.
Sydney Neuroimaging Analysis Center (SNAC) has been an extraordinary partner in our clinical plans for our lead asset. When we considered Australia for our clinical trial work in neurodegenerative disease, it was quickly apparent that SNAC was the right partner. We’ve been incredibly grateful for the support we’ve received from every team member at SNAC; the SNAC team members consistently provide a level of professionalism and solid collaboration in the rigorous clinical framework required for pharmaceutical clinical drug development. Clene looks forward to further partnership with SNAC.
— Rob Etherington , President & CEO , Clene Nanomedicine